Amid Risks, Generic Abilify Nod Buoys Outlook For Indian Firms
This article was originally published in PharmAsia News
Executive Summary
Japan’s Otsuka has finally lost the exclusivity grip in the U.S. over its atypical antipsychotic Abilify, as a band of generic drug makers including Teva, Torrent and Alembic queue up to make the most out of a thinning blockbuster opportunity.